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ABSTRACT The genes encoding the a and
.8 chains of the
T-cell antigen receptor isolated from a cytochrome c-specific,
major histocompatibility complex (MIC)-restricted murine T-
cell hybridoma were introduced into a mouse T-cell line of helper
lineage by electroporation. In order to examine the contributions
of those gene products to antigen and/or MHC specificity, the
resultant transfectants were tested for functional antigen and/or
MHC recognition. Only those transfectants that express both the
introduced genes (a and (3) contributed by the normal T cell can
respond specifically to the appropriate antigen/MHC pair. None
of the transfectants that express only one of the introduced genes
(a or/3) ofthe normal T cell, or paired hybrid genes (i.e., one gene
from the normal T cell and the other from the fusion partner), can
respond to the same combination of antigen and MHC product
recognized by the donor T cell. However, one clone expressing the
transfected genes that encode the a and (3 chains of the fusion
partner shows reactivity to the antigen-presenting cells even in the
absence of the antigens. These data suggest that the af8
heterodimer of the T-cefl receptor is required to define the fine
specificity of a T cell.
Thymus-derived (T)-lymphocyte recognition of products of
the major histocompatibility complex (MHC) is a major
factor controlling the vertebrate immune response. When
responding to foreign antigens, T cells recognize the foreign
molecules together with one ofthe selfclass I or class IIMHC
products expressed on the surface of the antigen-presenting
cell (APC; for review, see ref. 1), a property termed MHC
restriction. A relatively high proportion ofT cells are capable
of recognizing foreign- or allo-MHC products alone (2-5).
The T-cell antigen receptor responsible for MHC-restricted
antigen recognition is a disulfide-linked heterodimer consisting
oftransmembrane a and P chains. Both a and 1B chains contain
variable (V) and constant (C) regions homologous to immuno-
globulin V and C regions (for review, see refs. 6-8). Recently,
two sets of somatic cell genetic experiments indicated that a
particular a,8 T-cell receptor heterodimer is essential for re-
sponses to a defined antigen plus MHC product (9) or MHC
products alone (10). More direct evidence that the a18
heterodimer alone may define the dual specificity (antigen plus
MHC) of a given T-cell clone has also been reported (11, 12).
Neither the mouse a chain nor the mouse 1 chain, alone or when
expressed with a random human partner, mediates recognition
of either specific antigen or MHC molecule (12).
The helper-T-cell response to cytochrome c in mice is a
well-defined model for studying the T-cell response to restricted
antigen and MHC determinants (for review, see ref. 1). Helper
T (TH) cells specific for cytochrome c or its carboxyl-terminal
peptide analogues were raised in different MHC congenic
strains of mice and several Va and Va genes were isolated and
sequenced. It was shown that a single V,, gene segment (Va 1.1)
is expressed in 14 of 19 murine TH cells responding to
cytochrome c (13-15). This observation, as well as others, has
led to the proposal that the Va gene segment plays a central role
in controlling antigen specificity. We have examined the role the
Varil.) gene from one cytochrome c-specific TH hybridoma
(V1.9.2) plays in generating cytochrome c specificity by
transfecting it into a mouse cell line of the helper lineage singly
and with homologous and heterologous 3-chain genes. We
show here that only transfectants expressing both the a and the
,1 genes contributed by the V1.9.2 TH cell reconstitute the
antigen-specific, MHC-restricted fine specificity of the donor
cells, emphasizing the importance of both a and 13 chains in
antigen binding. One striking observation is that the expression
of the a and 13 genes contributed by the fusion partner endows
the recipient cell with the specificity to recognize particular
APCs in the presence or absence of antigen, suggesting that
these T-cell receptor molecules have allospecificity. These data
provide direct evidence that the a/3 heterodimer of the T-cell
receptor is required for the specific recognition of the
antigen-MHC pair and strongly suggest that a and ,1 chains are
involved in the direct recognition of MHC molecules in the
absence of antigen.
MATERIALS AND METHODS
Mice, Culture Medium, and Cell Lines. All mice were
obtained from The Jackson Laboratory. Supplemented Dul-
becco's modified Eagle's (DME) medium with the addition of
antibiotic G418 (2 mg/ml) was used as the G418-containing
medium. Hypoxanthine (15 ,ug/ml), aminopterin (0.2 ,g/ml),
and thymidine (8 ,ug/ml) were added to supplemented DME
medium to make HAT-containing medium. The EL-4G-12
lymphoma cell line (16) and the L-cell transfectants (17)
CA36.1.3 (expressing I-Ek molecules) and CA14.11.14 (ex-
pressing I-Ak molecules) were provided by R. T. Smith and
B. Malissen, respectively. The V1.9.2 hybridoma was pro-
vided by D. Hansburg (Fox Chase Cancer Center, Philadel-
phia, PA). The interleukin 2 (IL-2)-dependent cell lines
CTLL-2 and HT-2 (18) were provided by J. Kappler and P.
Marrack.
Plasmid Construction. Two clones containing full-length
cDNAs for V1.9.2 and BW5147 a chains, respectively, were
isolated (15) from a cDNA library of the V1.9.2 TH hybrid-
oma. The inserts were separately subcloned into a pSV2neo-
based vector to generate clones pV192aneo, pVl92a(-)neo,
and pBWaneo.
A genomic clone containing the rearranged V1.9.2 3-chain
gene (provided by N. Lan) was isolated (15). A 7.7-kilobase (kb)
Abbreviations: MHC, major histocompatibility complex; IL-2, in-
terleukin 2; APC, antigen-presenting cell; TH cell, helper T cell;
HAT, hypoxanthine/aminopterin/thymidine; SV40, simian virus 40;
PMA, phorbol 12-myristate 13-acetate; V, variable; C, constant; J,joining; D, diversity.
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fragment containing the complete V1.9.2 3 gene was then
subcloned into a pSV2gpt-based vector, generating clone
pV192.3gpt. A cDNA clone containing a 1.2-kb fragment cor-
responding to a full-length BW5147 3 gene (provided by R.
Barth, California Institute of Technology, Pasadena, CA) was
subcloned to generate clone pBW,8gpt. Two fragments, one
corresponding to the simian virus 40 (SV40) enhancer/promoter
and the other containing the SV40 polyadenylylation sites, were
introduced into pSV2neo (19) or pSV2gpt (20) to generate the
pSV2neo- or pSV2gpt-based vectors.
Transfection. EL-4G-12 cells were transfected by electro-
poration as described by Potter et al. (21).
IL-2 Production. IL-2 production by T-cell transfectants
was assayed as described by Shastri et al. (17).
RNA Preparation and Analysis. RNA was prepared from T
cells according to Chirgwin et al. (22). Total RNA was
electrophoresed in agarose/formaldehyde gels, blotted onto
nitrocellulose filters, and hybridized in 50% formamide
according to standard procedures (23). Posthybridization
washes were in 2x SSC/0.1% NaDodSO4 at room temper-
ature, followed by 0.2x SSC/0.1% NaDodSO4 at 500C. (lx
SSC is 0.15 M NaCl/15 mM sodium citrate, pH 7.)
DNA Probes. The V-specific fragment DNAs were isolated
from the plasmids pUC-Val (provided by J. Kobori, Cali-
fornia Institute of Technology), pUC-Vpl (provided by R.
Barth), and pUC-Vall (provided by A. Winoto, Massachu-
setts Institute of Technology, Cambridge, MA), labeled with
[,y-32P]ATP by polynucleotide kinase, and purified by gel
electrophoresis according to standard procedures (23). The
probes, with a specific activity of 1-3 x 108 cpm/,ug, were
used for hybridization.
RESULTS
Construction of Recombinant DNAs Containing the T-Cell
Receptor Genes and Gene-Transfer Experiments. The T-cell
receptor genes used for gene-transfer experiments were isolated
from the cloned murine T-cell hybridoma V1.9.2. This hybrid-
oma was derived by the fusion of T-cell blasts, from a
BlO.A(5R) mouse immunized with synthetic peptides analo-
gous to the carboxyl-terminal end of cytochrome c (DASp; see
Fig. 2 for peptide structure), and the T-cell line BW5147. The
V1.9.2 hybridoma responds strongly to an acetimidyl form of
the DASp peptide (AmDASp), but not to the DASp peptide,
when presented by BlO.A(5R) spleen cells (expressing EIEP
molecules) or B1O.A spleen cells (expressing E'E' molecules)
(24), thus exhibiting a heteroclitic response.
Although T-cell receptor molecules have not been detected
on the surface of the fusion partner BW5147, the a- and
,3-chain loci of this tumor cell line are rearranged and
transcribed. Upon fusion with normal T cells, the BW5147-
derived receptor molecules can be expressed on the hybrid-
oma surface (9, 10). Therefore, T-cell hybridomas can ex-
press as many as four different receptors due to combinato-
rial association between a and 3 chains contributed by the
normal T cell and the fusion partner. The antigen fine
specificity of the V1.9.2 hybridoma (i.e., the heteroclitic
reactivity toward AmDASp instead of DASp) could be
explained, for example, by the combination of the V1.9.2 a
and BW5147 /3 chains. To test this, both the V1.9.2 T-cell
receptor genes and the BW5147 T-cell receptor genes were
subcloned and used in the transfection experiments.
To be able to examine the contribution of the individual a
and ,8 chains to the observed antigen and MHC specificity of
the V1.9.2 hybridoma, we decided to subclone the two pairs
of genes into different selectable expression vectors-i.e.,
pSV2neo- and pSV2gpt-based vectors, respectively. The
pSV2neo and pSV2gpt vectors were modified by inserting
two DNA segments, one containing SV40 enhancer and
promoter and the other containing SV40 polyadenylylation
sites, to ensure the expression of the introduced a or/, genes.
A genomic fragment that contains the complete rearranged
V1.9.2 ,8 gene and a full-length BW5147 ,8 cDNA clone were
used in this study (Fig. 1 b and e). Because of the length of
the introns between the Ca gene segment and rearranged VcIJa
segments (25-27), full-length V1.9.2 and BW5147 a cDNA
clones were used rather than genomic DNA fragments (Fig.
1 a and d). One construct in which the V1.9.2 a gene is
opposite to the SV40-driven transcriptional orientation was
also isolated and served as a control in the transfection
experiments (Fig. ic).
The plasmid constructs were individually transfected or
cotransfected in af3 combinations into the EL-4G-12 lymphoma
cells by electroporation (21). The HAT-sensitive EL4G-12 cell
line was chosen as the recipient because of its ability to secrete
IL-2 upon stimulation with T-cell mitogens (16). From several
independent electroporation experiments, drug-resistant clones
were isolated by appropriate selection. The resultant transfect-
ants obtained from these gene-transfer experiments are sum-
marized in Table 1 and described below in detail.
Function of Transfected Genes, To determine which com-
binations of the introduced T-cell receptor genes were
expressed and responsive to specific antigen/MHC, all the
G418- and HAT-resistant clones (double transfectants) and
some of the G418- or HAT-resistant clones (single transfect-
ants) were screened for responses to the DASp or AmDASp
antigens together with appropriate APCs [spleen cells from
B10.A(5R) mice]. The mitogen PMA was used in the screening
experiments as a nonspecific stimulator to ensure that the
transfectants retained the ability to secrete IL-2. As shown in
a b c
d e
LE
FIG. 1. Recombinant DNA constructs. (a) A full-length V1.9.2
a-chain cDNA clone was removed from a XgtlO clone by partial
digestion with EcoRI and subcloned into a pSV2neo-based vector.
(b) A Sal 1-HindIII genomic DNA fragment containing the complete
rearranged V1.9.2 /3-chain gene [including constant (C), joining (J),
diversity (D), variable (V), and leader (L) segments] was subcloned
into a pSV2gpt-based vector. (c) The same V1.9.2 a cDNA clone
used in a was subcloned into a pSV2neo-based vector in the opposite
orientation with respect to the SV40 enhancer/promoter. (d and e)
Two cDNA clones containing full-length BW5147 a and /8 genes,
respectively, were subcloned into pSV2neo-based (d) and pSV2gpt-
based (e) vectors separately. The Pvu I-HindlIl fragments, corre-
sponding to the SV40 enhancer/promoter, and the Rsa I-EcoRI
fragment, containing the SV40 polyadenylylation sites, were intro-
duced into pSV2neo or pSV2gpt at the EcoRI site to generate the
pSV2neo- or pSV2gpt-based vector. The a or /3 gene was then
subcloned into the modified vector at the junction of the two inserted
segments. Open boxes indicate the inserts containing the T-cell
receptor genes. The pBR322 DNA is represented by a wavy line.
SV40 sequences are represented by solid lines, and the SV40
enhancer/promoter region is represented by a heavier solid line.
Abbreviations: E, EcoRI site; Ampr, ampicillin-resistance gene;
neor, the aminoglycoside 3'-phosphotransferase gene; gpt, E. coli
xanthine (guanine) phosphoribosyltransferase gene. Arrows indicate
direction of transcription.
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Table 1. Isolated T-cell transfectants
No. of No. of
drug- analyzed/
resistant responsive Designation of
Plasmid DNA clones clones analyzed clones
pV192aneo (A) >100 6/0 T-V192a-1 to -6
pVl92,Bgpt (B) >100 6/0 T-V192,8-1 to -6
pBWaneo (C) >100 NT None
pBW/3gpt (D) >100 NT None
A + B 17 17/7 T-V192aI3-1 to -17*
A + D 10 10/0 T-V192aBWJ-1 to -10
C + B 15 15/0 T-BWaV192f3-1 to -15
C + D 4 4/1 T-BWaI3-1 to -4t
pVl92a(-)neo + B 4 4/0 T-V192a(-)/3-1 to -4
pVl92a(-)neo + D 5 5/0 T-V192a(-)BW,8-1 to -5
Plasmid DNAs were introduced into EL-4G-12, a HAT-sensitive
lymphoma cell line, by electroporation. After 48 hr, drug-resistant
clones were selected in the presence of G418 for pV192aneo or
pBWaneo transfections, HAT for pV192,3gpt or pBW/3gpt
transfections, and G418 plus HAT for cotransfection. Drug-resistant
clones were screened for specific IL-2-production response induced by
antigen (AmDASp or DASp peptide) plus APCs [spleen cells from
B1O.A(5R) mouse] or APCs alone. IL-2 production by T-cell transfect-
ants were assayed as described in the legend to Fig. 2. All the analyzed
clones have retained the ability to produce IL-2 upon nonspecific
stimulation with the mitogen phorbol 12-myristate 13-acetate (PMA) a
property of the untransfected EL-4G-12 cells. NT, not tested.
*Transfectants T-V192ap-1 to -7 are the seven clones that respond
to AmDASp peptide in the context of B1O.A(5R) APCs. They do not
respond to DASp peptide in association with the appropriate APCs
or to APCs alone (see Fig. 2).
tT-BWa,3-l is the clone that responds to B1O.A(5R) APCs in the
presence or absence of either of the two antigens (see Fig. 2).
Table 1 and Fig. 2, of the 17 double transfectants that received
a and ,B genes of V1.9.2 cell, 7 exhibited the same response
phenotype as the donor V1.9.2 hybridoma. Reproducibly they
responded to the AmDASp peptide, but not to the DASp
peptide, in association with APCs. They did not respond to
either of the two antigens alone or to APCs alone. Neither the
tested single transfectants nor the double transfectants that
received the hybrid aB paired genes (i.e., one of the two genes
derived from the V1.9.2 cell and the other from the fusion
partner BW5147 cell) responded to either of the two antigens
presented by BlO.A(5R) APCs. Interestingly, one of the clones
transfected with BW5147 a and /8 genes (T-BWa/3-1) showed
reactivity with the BlO.A(5R) APCs alone. The presence of
either of the two antigens did not inhibit or enhance this
reactivity (Fig. 2). This transfectant also exhibited a strong
response to spleen cells from B1O.A mice but not from B6 mice
(data not shown), consistent with the proposition these genes
encode an alloresponse against MHC molecules, presumably
I-Ek. We provisionally defined this transfectatit as an alloreac-
tive clone.
Thus, by transfecting cells with V1.9.2 a and P3 genes, we are
able to isolate clones that have the same reactivity as the V1.9.2
parent line. After transfection with BW5147 a and ,B genes, we
isolated one putative alloreactive clone. No clone that can
specifically react to DASp in association with BlO.A(5R) APCs
was identified with this antigen-response screening assay.
Transcription of Transfected a and 13 Genes. To determine
which transfectants expressed a and/or ,3 genes, we analyzed
their RNA transcripts by blot hybridization analyses using
probes specific for the Va and Vq genes of the V1.9.2 and
BW5147 cell lines. Total cytoplasmic RNAs were analyzed
using a VaJJ.J-specific probe from V1.9.2 hybridoma cells
(Fig. 3a). The untransfected EL-4G412 cells (lane 1) and cells
that received the V1.9.2 a and 83 genes but fail to respond to
AmDASp/APC (lane 2) did not show hybridization. All
AmDASp/APC-reactive clones and some of the transfectants
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FIG. 2. IL-2 production of T-cell transfectants in response to
antigen and/or MHC. The following stimulation protocols were
employed: APCs [B1O.A(5R) spleen cells] alone (open bars); 20 AM
DASp peptide plus APCs (stippled bars); 20 ,M AmDASp peptide
plus APCs (solid bars); or PMA (20 ng/ml) (hatched bars). DASp and
AmDASp antigens (shown at top in standard one-letter amino acid
symbols) are synthetic derivatives of the moth cytochrome c
carboxyl-terminal peptide. A circled K denotes an acetimidylated
lysine and a dash denotes identity. About 101 T cells were cultured
in 0.2 ml of medium with 5 x 105 mitomycin C-treated spleen cells
(APCs) in the presence or absence of antigen. After 24 hr, 50 ,ul of
the culture supernatant was added to 5 x 103 cells of the IL-2-
dependent cell line CTLL-2 or HT-2, to a final volume of 100 ,Il.
Results are expressed as the amount of [3H]thymidine incorporated
into the IL-2-dependent cells during the last 4 hr of a 24-hr culture.
None of the tested T cells produced any detectable IL-2 when
stimulated by either of the two antigens alone. Similar results were
obtained by using 10 tAM antigen (data not shown). Each bar
represents the mean of [3H]thymidine incorporation of IL-2-depen-
dent CTLL-2 cells from triplicate cultures. The same pattern of
response was obtained when the IL-2 dependent cell line HT-2 was
used (data not shown). The results obtained from all the nonrespon-
sive clones listed in Table 1 are similar to that obtained from clone
T-V192aBW/3-3. The patterns of IL-2-production responses among
each individual transfectant T-V192a,3-1 to -7 are the same, and the
results for T-V192af3-7 are shown as an example for the seven
responsive clones.
belonging to the T-V192aBWf category, as well as some of the
single transfectants that received only the V1.9.2 a gene,
showed one distinct transcript of 2.8 kb, which is larger than the
authentic V1.9.2 a transcript of 1.8 kb (lane 3). One example of
each case is shown in Fig. 3a (lanes 4-6). Presumably, this
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FIG. 3. RNA blot analysis of transfectants for expression of the
V1.9.2 a gene (a), the BW5147 a gene (b), and the V1.9.2 or BW5147
,3 genes (c). Total cytoplasmic RNA (20 ,ug) was electrophoresed in
a 1% agarose gel containing 2.2 M formaldehyde, transferred to
nitrocellulose filters, and hybridized with probes specific for ValL.1
(a), Va1 (b), or Via (c), respectively. The relative sizes (in kb) of the
hybridizing RNAs are indicated to the right of each autoradiogram.
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2.8-kb RNA is the result of new RNA initiation and/or termi-
nation sites. An increase in the transcript size was also observed
in previous studies (12, 28) of transfectants expressing T-cell
receptor cDNAs cloned into similar vectors.
A probe specific for the Va gene of BW5147 (V,,1) (29)
demonstrated that no BW5147 a RNA was expressed either
in the untransfected EL-4G-12 cells or in some of the
T-BWaV192J3 and T-BWaJ3 transfectants (data not shown).
At least two transfectants (T-BWaV192P-3 and -7) and the
alloreactive clone, T-BWa08-1, did show hybridization.
Again, the two larger transcripts (2.8 kb and 3.2 kb, Fig. 3b)
that hybridized to the probe probably resulted from a com-
bination of different RNA initiation and/or termination sites
of the introduced DNA.
Since both the V1.9.2 and BW5147 cells use the same VpJ
gene segment (30), most of the RNAs of the transfectants
analyzed above were examined using a V,91-specific probe (Fig.
3c). No VpJ RNA was detected in EL-4G-12 cells, in cells
transfected with only the V1.9.2 a gene, or in the nonresponder
clone T-V192af3-10 (data not shown). All the other tested
transfectants had the Vq1 transcripts. Cells transfected with the
,3 gene of V1.9.2, derived from a genomic DNA fragment, gave
a band at 1.3 kb, which is the normal size for a complete VDJC
transcript (lane 1) and an additional transcript of 2.7 kb (lanes
2 and 3). Transfectants generated with the cDNA of BW5147 P
gene gave a larger Vp1 transcript (2.7 kb, lanes 4 and 5). Again,
the larger transcripts were probably the result of new RNA
initiation and/or termination sites.
The results of antigen-stimulation assays and RNA blot
analysis suggest that only transfectants receiving and ex-
pressing both a and ,B genes of V1.9.2 T-cell receptor can
recognize the AmDASp peptide associated with APCs, the
functional property of the V1.9.2 hybridoma. None of the
transfectants that express the V1.9.2 a or 1B gene alone
(paired with the other gene contributed by either the recipient
cell or BW5147 introduced by gene transfer) can respond to
AmDASp and/or MHC.
Functional Recognition by Transfectants T-V192aIp-1 to -7
Is Antigen-Specific and MHC-Restricted. To further extend
the results that demonstrate the AmDASp-reactive transfect-
ants do respond to antigen/MHC in the same manner as
V1.9.2 hybridoma, we tested all seven transfectants for
recognition specificity in detail.
The panel of transfectants was tested for IL-2 production
in the presence of various concentrations of antigen and/or
APCs bearing different MHC molecules. The untransfected
EL-4G-12 cells did not respond to any of the tested APCs in
the presence or absence of either of the two antigens
(AmDASp and DASp peptides), even at antigen concentra-
tions up to 200 uM (data not shown). The donor V1.9.2
hybridoma responded strongly to the AmDASp peptide, but
not to the DASp peptide, in the context of spleen cells from
BlO.A(5R) mice or B1O.A mice (Fig. 4a), similar to the results
previously obtained (24). In addition, the V1.9.2 hybridoma
showed a good response to the AmDASp peptide, but not to
the DASp peptide, when presented by L-cell transfectants
CA36.1.3 (expressing I-Ek molecules). It failed to respond to
either of the two antigens presented by spleen cells from B6
mice (expressing I-Ab molecules) or BALB/c mice (express-
ing both the I-Ad and I-Ed molecules) (data not shown) or by
L-cell transfectants CA14.11.14 (expressing I-Ak molecules)
(Fig. 4a). The seven reactive transfectants showed the same
antigen and MHC fine specificity as the V1.9.2 hybridoma
described above, although the levels of IL-2 production were
slightly different among these positive clones. Therefore, the
transfectants expressing complete V1.9.2 a and genes
respond to the combination of AmDASp peptides and I-Ek
molecules, as does the donor V1.9.2 hybridoma. One exam-
ple of the IL-2-production responses of the seven positive
transfectants is shown in Fig. 4b.
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FIG. 4. Antigen specificity and MHC restriction of the V1.9.2 and
T-V192a/3-7 cells. The V1.9.2 hybridoma (a) or T-V192a/3-7 (b) cells
(105) were cultured with the indicated concentration of AmDASp
peptide (A, *, e, and m; solid lines) or DASp peptide (A. o, o. and i;
broken lines) presented by spleen cells from B10.A(5R) mouse (A. A)
or B10.A mouse (*, o) or by L-cell transfectant CA36.1.3 (e, o) or
CA14.11.14 (n. a). IL-2 production by T cells was assayed as
described in the legend to Fig. 2. Each point represents the mean of
triplicate cultures.
Further evidence for the direct involvement of the I-Ek
molecules in the specific functional antigen/MHC corecogni-
tion was obtained from antibody-blocking studies. The IL-2
production of the V1.9.2 hybridoma and the transfectants
induced by AmDASp peptide in the presence of the I-Ek_
expressing L-cell transfectants was inhibited by the monoclonal
anti-I-Ek antibody 10B, but not by the monoclonal anti-H-2Kk
antibody 84.17.2 (17) (Table 2). This demonstrates that it is the
same MHC molecules that restrict antigen recognition by both
the V1.9.2 hybridoma and the positive transfectants.
DISCUSSION
Our data confirm the recent observation that the T-cell receptor
a/3 heterodimer can transfer specific antigen/MHC recognition
from one class II-restricted TH cell to another (12). Transfection
ofthe EL-4G-12 cells with the a- and/or /-chain genes ofV1.9.2
and BW5147 cells generated cells that expressed the introduced
gene messages. Only transfectants in which both a and genes
of the V1.9.2 T-cell receptor are transcribed can respond
specifically to the AmDASp peptide presented by appropriate
MHC molecules, as the V1.0.2 hybridoma. Transfectants ex-
pressing only V1.9.2 a or gene message show no detectable
Table 2. Effect of anti-MHC antibodies on the IL-2-production
response of the T-V192af3-7 transfectant
[3H]Thymidine incorporation,
cpm x 10-3
T cells Stimulus No antibody 10B 84.17.2
EL-4G-12 AmDASp + APCs 0.6 0.5 0.6
APCs 0.5 0.4 0.4
T-V192a3-7 AmDASp + APCs 22.5 6.7 18.8
APCs 1.6 1.4 1.5
V1.9.2 AmDASp + APCs 17.1 4.1 14.1
APCs 2.5 2.2 2.2
T cells were stimulated to produce IL-2 in the presence of
AmDASp peptide (10 puM) plus APCs (CA36.1.3)-or of APCs alone.
Cultures received either no antibody, antibody 10B (anti-I-Ek, 4
,ug/ml), or antibody 84.17.2 (anti-H-2Kk, 4 Ag/ml). The monoclonal
antibodies were kindly provided by M. Pierres. IL-2 production was
assayed as described in the legend to Fig. 2. Values for thymidine
incorporation are means of triplicate cultures. Cells were able to
produce IL-2 when stimulated by PMA in the presence of either of
the two antibodies (data not shown).
Immunology: Kuo and Hood
Proc. Natl. Acad. Sci. USA 84 (1987)
response to specific antigen/MHC. Therefore, these data
strongly suggest that both the a and 1P chains ofa T-cell receptor
are required for defining the antigen fine specificity and MHC
restriction of a T cell.
Analysis of other transfectants that transcribed the intro-
duced single V1.9.2 a or ,3 gene, or the paired hybrid genes
(i.e., one gene from the V1.9.2 cell and the other from the
BW5147 cell) allowed us to determine whether the combina-
torial association betweeh a and 3 chains plays a role in
defining the heteroclitic reactivity of the V1.9.2 hybridoma.
These studies also allowed us to examine the ability of
individual chains of the T-cell receptor from the V1.9.2 cell
to mediate functional antigen or MHC recognition indepen-
dently. All the analyzed transfectants that expressed only one
ofthe V1.9.2 a and /3 gene messages or messages of the paired
hybrid genes failed to respond to antigen (AmDASp or DASp
peptides) alone, to MHC molecules of BlO.A(5R) APCs
alone, or to both antigen and MHC molecules together. Thus,
the following observations can be made. First, the hetero-
clitic specificity to AmDASp/MHC of the V1.9.2 hybridoma
is not due to combinatorial association between a and 3
chains contributed by the normal T cell (V1.9.2) and the
fusion partner (BW5147). Second, V1.9.2 and BW5147 cells
use the same V1 segment but a different D-J region in L3
chains (30), yet transfectants that transcribe the V1.9.2 a
gene and the BW5147 ,1 gene do not respond to the antigen/
MHC combination that stimulates the T-V192a,3 transfect-
ants and the V1.9.2 hybridoma. This is direct evidence that
the junctional region (V-D-J) in /3 chain can be important for
the specificity in antigen/MHC recognition. This observation
correlates with results obtained from DNA sequence analysis
of genes isolated from T cells with different specificity (14,
31) and suggests that V-D-J joining could be one of the
important mechanisms for generating the diversity of the
T-cell repertoire. Third, the hybrid T-cell receptors contain-
ing one V1.9.2 chain cannot mediate detectable recognition
either of cytochrome c-related antigen or of MHC (I-Ek)
molecules, although the Vc, segment of V1.9.2 (VJ 1.1) was
shown to be associated with a large fraction of the T-cell
responses of mice to cytochrome c (14, 15). We cannot,
however, rule out the possibility that (i) the level of expres-
sion of the introduced T-cell receptor gene products on the
surface of the recipient cells might be too low to permit
effective responses or (ii) the structure of the EL-4G-12 or
BW5147 partner chain might sterically hinder the V1.9.2
T-cell receptor chain from binding to the antigen or MHC
molecules alone.
The expression of messages of both the a and the 13 genes
of BW5147 has endowed the recipient cell (T-BWaB-1) with
the ability to recognize MHC molecules. Whether this reac-
tivity is due to the expression of a receptor made up of a and
,1 chains from BW5147, or a combination of receptor chains
of BW5147 and EL-4G-12, is not known. Study of the
functional properties of the single transfectants generated in
this study would answer this question. Regardless, the
generation of an alloreactive clone by in vitro gene transfer
demonstrates that the transfection experiment has provided
a means to directly examine the role of T-cell receptor
molecules in alloreactive T cells.
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